News | October 09, 2024
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
USFDA completes PAI of Lupin’s biotech facility in Pune
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Subscribe To Our Newsletter & Stay Updated
